BetterLife Pharma (BETRF) Liabilities and Shareholders Equity (2011 - 2026)
BetterLife Pharma (BETRF) posted quarterly Liabilities and Shareholders Equity of $176852.7 for Q2 2026, up 8.54% year-over-year from $162934.7 in Q2 2025, and up 11.61% quarter-over-quarter from $158455.4 in Q1 2026.
BetterLife Pharma (BETRF) Liabilities and Shareholders Equity (2011 - 2026) Analysis & Trends
BetterLife Pharma's Liabilities and Shareholders Equity history runs 16 years deep, the most recent figure standing at $176852.7 for Q2 2026.
- In Q2 2026, Liabilities and Shareholders Equity rose 8.54% year-over-year to $176852.7; the TTM figure through Apr 2026 stood at $665153.1 (down 21.61% YoY), while the FY2026 annual figure was $158455.4, changed 0.01% from the prior year.
- Liabilities and Shareholders Equity for Q2 2026 stood at $176852.7, up from $158455.4 in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $917571.6 in Q1 2022, with the low at $55402.2 in Q1 2023.
- The 5-year median for Liabilities and Shareholders Equity is $210201.6 (2022), against an average of $296841.2.
- The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity plunged 95.78% in 2022, then jumped 333.6% in 2024.
- BetterLife Pharma's Liabilities and Shareholders Equity stood at $210201.6 in 2022, then surged by 78.77% to $375768.6 in 2023, then sank by 47.11% to $198725.6 in 2024, then dropped by 16.01% to $166910.3 in 2025, then gained by 5.96% to $176852.7 in 2026.
- Business Quant data shows BETRF's Liabilities and Shareholders Equity at $176852.7 in Q2 2026, $158455.4 in Q1 2026, and $166910.3 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | BetterLife Pharma | 36.45 Mn | 36.42 Mn | - | 176,852.69 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 176,852.69 |
| Jan 31, 2026 | 158,455.44 |
| Jul 31, 2025 | 166,910.29 |
| Apr 30, 2025 | 162,934.67 |
| Jan 31, 2025 | 158,469.98 |
| Oct 31, 2024 | 198,725.58 |
| Jul 31, 2024 | 328,420.56 |
| Apr 30, 2024 | 584,513.58 |
| Jan 31, 2024 | 240,221.59 |
| Oct 31, 2023 | 375,768.62 |
| Jul 31, 2023 | 299,374.35 |
| Apr 30, 2023 | 533,835.18 |
| Jan 31, 2023 | 55,402.18 |
| Oct 31, 2022 | 210,201.63 |
| Jul 31, 2022 | 194,873.96 |
| Apr 30, 2022 | 283,767.69 |
| Jan 31, 2022 | 917,571.58 |
| Oct 31, 2021 | 2.41 Mn |
| Jul 31, 2021 | 4.62 Mn |
| Apr 30, 2021 | 1.14 Mn |